4 Sep 2018 10:00
Woodford Patient Capital Trust plc
Woodford Patient Capital Trust update: a summer of milestones
LONDON, 04 September 2018
Several of the portfolio companies held in Woodford Patient Capital Trust plc (WPCT) reached significant milestones during the summer. The milestones are highlighted in Woodford Investment Management's August roundup. They include Autolus' successful IPO, Proton Partners treating the first cancer patient with proton beam therapy in the UK and opening its second centre, and Kymab moving its atopic dermatitis treatment to a phase II trial.
Further details are provided on the links below and at www.woodfordfunds.com
Autolus
Autolus is at the forefront of a revolutionary immuno-oncology treatment, dubbed the 'living medicine', that is offering new hope to patients suffering from blood-related cancers such as lymphoma and myeloma. In June, it successfully transitioned from a private business to a public one via a successful IPO on the Nasdaq.Read more
Cequr
Cequr is developing simple-to-use insulin-based treatments, including an injection-free device that lasts longer than insulin patches used today. In July, the company acquired a approved type 2 diabetes product called One Touch Via from Johnson & Johnson, which it is planning to commercialise next year.Read more
Federated WirelessIn July, the Federal Communications Commission (FCC) in the US issued a public notice that signals the start of commercial developments in shared spectrum. This has formalised the path for commercialistaion and Federated Wireless, founded by Allied Minds, is now well-positioned to see its large customers offering commercial services in the 4th quarter.
Read more
Genomics
Genomics brings together vast swathes of genomic data to improve the drug discovery process - making it faster, more cost-efficient and increasing the likelihood of success. In August, the company successfully completed a funding round and secured a collaboration with global pharmaceutical company, Vertex.Read more
Immunocore
Spun out of Oxford University in 2008, Immunocore is at the forefront of the fast-growing field of immuno-oncology (treatments that use the immune system to kill cancers). In July it announced the start of a phase I study for its second ImmTAC molecule (IMCnyeso) in patients with solid tumours - as part of an ongoing collaboration with GlaxoSmithKline.Read more
Kymab
Kymab, which is also backed by the Wellcome Trust and the Bill & Melinda Gates Foundation, is developing monoclonal antibody treatments - a type of therapeutic drug - to counter illnesses such as atopic dermatitis and cancer. In July, it announced that its potential atopic dermatitis treatment called KY1005 was moving to a phase II trial following positive results from the phase I study in healthy volunteers.Read more
Oxford Nanopore
Oxford Nanopore is developing a new generation of DNA sequencers, some of which are small, portable and affordable. These are also the world's only sequencers that can deliver DNA analysis in real-time. In June, full year results highlighted that its revenues tripled in 2017.Read more
Proton Partners
The UK's first high energy proton beam therapy provider announced in June that it had treated its first patient with proton beam therapy at its Newport centre - also a first for the UK. In August, the company announced the opening of its second cancer centre in Northumberland.
Read more
Seedrs
In August, Seedrs, the crowdfunding platform, announced that it had invested more than £400m into campaigns funded on the platform since launch and had signed a partnership with US platform, Republic. The company has also launched its auto-invest product - another operational milestone for the business.
Sensyne Health
The company analyses NHS patient data using artificial intelligence algorithms to help healthcare companies discover new medicines. Founded by Lord Drayson the former science minister, the company (formerly known as Drayson Health) signed exclusive partnerships with three NHS trusts in July, and in August, successfully listed on the London Stock Exchange.Read more
For further information, please contact:
Four Broadgate
Roland Cross / Jonathan Atkins / Matt Jones
020 3697 4200
woodford@fourbroadgate.com
Notes to editors:
Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of WPCT. These statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. Nothing in this announcement should be construed as a profit forecast.
About Woodford Investment Management:
Woodford Investment Management Limited is an asset management company built on a founding philosophy of transparency and simplicity. Launched in May 2014, the company has more than £12.5bn assets under management and advice.
Woodford Investment Management Ltd
9400 Garsington Road Oxford OX4 2HN
+44 (0)1865 809 000
info@woodfordfunds.com
Authorised and regulated by the Financial Conduct Authority
Registered in England and Wales. Number 10118169
ENDS